LICENSING AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended
	Dec. 28, 2020	Nov. 30, 2019	May 17, 2017	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
License fees	$ 250,000
License agreement description	(the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
Continuing royalty description						Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelzTM
Amortization expenses				$ 23,021	$ 16,771	$ 69,063	$ 50,021
Stemspine LLC [Member]
Royalty payment percentage			5.00%
Non-royalty sublease income percentage.			50.00%
Patent License Agreement [Member]
License fees						250,000
Amortization expenses				6,250		18,750
Carrying value of patent				231,250		$ 231,250		$ 250,000
Expiration period of finite-lived intangible assets						2030
Expected annual amortization amount				25,000		$ 25,000		25,000
Patents [Member]
Amortization expenses				2,493		7,479
Carrying value of patent				43,481		43,481		50,960
Expected amount of amortization						$ 9,972
Expiration period of finite-lived intangible assets						2026
Patents [Member] | Creative Medical Health Inc [Member]
Amortization expenses				293	293	$ 879	882
Carrying value of patent				213,799		213,799		248,254
Expected amount of amortization						$ 46,000
Expiration period of finite-lived intangible assets						2027
Initial payment		$ 300,000	$ 100,000
Percentage of discount on the basis of recent trading price			30
Debt conversion, converted instrument, amount						$ 50,000
Share price for two or more consecutive trading days			0.01
Debt conversion, converted instrument, shares issued						89,286
Patents [Member] | Creative Medical Health Inc [Member] | Scenario One [Member]
Payments upon signing agreement with university for the initiation of an IRB clinical trial			$ 100,000
Payments upon completion of the IRB clinical trial			200,000
Payments in the event of commercialization of technology			300,000
Patents [Member] | Creative Medical Health Inc [Member] | Scenario Two [Member]
Payments upon filing an IND with the FDA			100,000
Payments upon dosing of the first patient in a Phase 1-2 clinical trial			200,000
Payments upon dosing of the first patient in Phase 3 clinical trial			$ 400,000
Patents [Member] | Stemspine LLC [Member]
Amortization expenses				2,500		$ 7,500
Carrying value of patent				57,500		57,500		65,000
Expected amount of amortization						$ 10,000
Expiration period of finite-lived intangible assets						2027
Patents [Member] | Multipotent Amniotic Fetal Stem Cells License Agreement [Member]
Amortization expenses				11,485	$ 11,485	$ 34,455	$ 34,455
Carrying value of patent				$ 4,670		4,670		$ 5,549
Expected amount of amortization						$ 1,172
Expiration period of finite-lived intangible assets						2026